Menon, U;
Griffin, M;
Gentry-Maharaj, A;
(2014)
Ovarian cancer screening - current status, future directions.
Gynecol Oncol
, 132
(2)
pp. 490-495.
10.1016/j.ygyno.2013.11.030.
![[thumbnail of 1-s2.0-S0090825813013577-main.pdf]](https://discovery-pp.ucl.ac.uk/style/images/fileicons/application_pdf.png) |
PDF
1-s2.0-S0090825813013577-main.pdf Download (207kB) |
Abstract
Evidence of a mortality benefit continues to elude ovarian cancer (OC) screening. Data from the US Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening trial which used a screening strategy incorporating CA125 cut-off and transvaginal ultrasound has not shown mortality benefit. The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) is using the Risk of Ovarian Cancer (ROC) time series algorithm to interpret CA125, which has shown an encouraging sensitivity and specificity however the mortality data will only be available in 2015. The article explores the impact of growing insights into disease etiology and evolution and biomarker discovery on future screening strategies. A better understanding of the target lesion, improved design of biomarker discovery studies, a focus on detecting low volume disease using cancer specific markers, novel biospecimens such as cervical cytology and targeted imaging and use of time series algorithms for interpreting markers profile suggests that a new era in screening is underway.
| Type: | Article |
|---|---|
| Title: | Ovarian cancer screening - current status, future directions. |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.ygyno.2013.11.030 |
| Publisher version: | http://dx.doi.org/10.1016/j.ygyno.2013.11.030 |
| Additional information: | © 2014 The Authors. Published by Elsevier Inc. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| Keywords: | UKCTOCS, biomarkers, imaging, ovarian cancer, screening |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/1418410 |
Archive Staff Only
 |
View Item |
